According to the website of the National Medical Products Administration, recently, the National Medical Products Administration approved Boehringer Ingelheim International GmbH's application for Class 1 innovative drug Namistat tablets (trade name: Boyouwei), which is suitable for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). The drug's launch provides patients with new treatment options. (New Society)
Edit:Wang Shu Ying Responsible editor:Li Jie
Source:people.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email:lwxsd@liaowanghn.com